Latest news with #AAT
Yahoo
6 days ago
- Business
- Yahoo
AAT and University of Exeter accounting degree apprenticeship
The Association of Accounting Technicians (AAT) and the University of Exeter have collaborated to introduce a new Accounting Finance Manager degree apprenticeship, starting in September 2025. This programme combines the AAT Level 4 Diploma in Professional Accounting with a Bachelor's degree, integrating academic learning with workplace-relevant training. Apprentices will complete the AAT Level 4 Diploma during their first year, gaining early qualifications that provide exemptions for certain ACCA and CIMA exams, supporting their path to becoming chartered accountants. The course structure was developed with input from the University of Exeter's employer partners to align with current needs in the finance sector. The University of Exeter Centre for Degree Partnerships director Rachael Johnstone said: 'The Accounting Finance Manager Degree Apprenticeship opens new doors for aspiring accounting and finance professionals, combining academic excellence with practical industry-focused skills to create a truly inclusive pathway to success. 'Our partnership with AAT is a transformational step in our mission to widen participation in Higher Education and diversify the accounting and finance industries. We're excited to welcome our first cohort in September 2025.' The initiative seeks to address skill gaps in finance and open pathways for school leavers and career switchers from varied backgrounds to enter the profession through a degree apprenticeship. UK businesses can fund employee training using the Skills and Growth levy, enabling them to develop and recruit skilled accounting professionals to contribute to economic development. AAT Customer, Partnerships and Innovation executive director Claire Bennison said: 'Our collaboration with the University of Exeter is a game-changer for those seeking a career in finance. 'For the first time, our Level 4 Diploma qualification will be obtained within the first year ensuring students will be able to step into the finance world sooner. 'This degree apprenticeship ensures students are on track to obtain practical accounting skills they will draw on throughout their careers. It demonstrates that there are many routes to professional success, whether you're starting out after school or looking to upskill later in life. 'By equipping apprentices with globally recognised qualifications and a clear pathway, we're empowering individuals and supporting employers in building a skilled, diverse workforce.' "AAT and University of Exeter accounting degree apprenticeship" was originally created and published by International Accounting Bulletin, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Miami Herald
15-07-2025
- Business
- Miami Herald
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsinLead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. "With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis." "We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step." "We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area." AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties. About AATec Medical AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit and follow AATec on LinkedIn. About Northway Biotech Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit Northway Biotech Contact: Prof. Vladas Algirdas BumelisCEO and Chairman of the AATec Medical Contact: Dr. Rüdiger Jankowsky, CEOinfo@ Media Contact: MC ServicesKatja Arnold, Julia von Hummelaatec-medical@ +49 (0)89 2102280 SOURCE: Northway Biotech press release
Time of India
11-07-2025
- Automotive
- Time of India
Tata Motors, M&M, three others may raise ₹2,000 cr and PLI claims
Tata Motors , Mahindra & Mahindra (M&M), Bajaj Auto , Ola Electric Technologies and TVS Motor Company could raise claims totalling more than ₹2,000 crore this fiscal year under the Production Linked Incentive (PLI) scheme for automobiles, according to a government assessment. Officials said these claims are for investment and incremental sales goals achieved in the fiscal year ended March 31. Bajaj Auto is expected to make the highest claim of ₹630 crore, followed by Tata Motors at ₹409 crore, and Ola Electric at ₹380 crore, officials said. TVS Motor and M&M could raise claims of ₹330 crore and ₹283 crore, respectively. Despite the substantial claims, it would still fall short by ₹702 crore from the FY26 Budget estimates. "Companies have more time to seek claims," a senior official told ET, noting beneficiaries can submit applications till September. Heavy industries minister HD Kumaraswamy reviewed the PLI scheme's performance on Thursday. He directed the ministry to ensure handholding of applicants on operational aspects, claims, and ensuring domestic value addition (DVA), according to officials. "The scheme has so far attracted significant domestic investments worth ₹29,576 crore until March 2025," Kumaraswamy said in a statement after the review. "Going forward, we are committed to regular industry workshops, faster claim disbursals, and robust support to stakeholders paving the road for a self-reliant and globally competitive auto sector," he added. Officials said claims worth ₹322 crore were released under the scheme goals achieved in FY24 to Tata Motors, M&M, Ola Electric, and Toyota Kirloskar Auto Parts (TKAP). This is despite more than 80 companies initially getting approvals under the scheme. The Centre approved the PLI for automobiles in September 2021 with a ₹25,938 crore budgetary outlay. The scheme aims to overcome cost disabilities of the domestic industry for manufacturing Advanced Automotive Technology (AAT) products in India. The industry needs to make fresh investments for indigenous manufacturing of AAT products and create jobs to claim incentives.
Time of India
10-07-2025
- Automotive
- Time of India
Tata Motors, M&M, three others may raise Rs 2k cr and PLI claims
New Delhi: Tata Motors , Mahindra & Mahindra (M&M), Bajaj Auto , Ola Electric Technologies and TVS Motor Company could raise claims totalling more than ₹2,000 crore this fiscal year under the Production Linked Incentive (PLI) scheme for automobiles, according to a government assessment. Officials said these claims are for investment and incremental sales goals achieved in the fiscal year ended March 31. Bajaj Auto is expected to make the highest claim of ₹630 crore, followed by Tata Motors at ₹409 crore, and Ola Electric at ₹380 crore, officials said. TVS Motor and M&M could raise claims of ₹330 crore and ₹283 crore, respectively. Despite the substantial claims, it would still fall short by ₹702 crore from the FY26 Budget estimates. "Companies have more time to seek claims," a senior official told ET, noting beneficiaries can submit applications till September. Heavy industries minister HD Kumaraswamy reviewed the PLI scheme's performance on Thursday. He directed the ministry to ensure handholding of applicants on operational aspects, claims, and ensuring domestic value addition (DVA), according to officials. "The scheme has so far attracted significant domestic investments worth ₹29,576 crore until March 2025," Kumaraswamy said in a statement after the review. "Going forward, we are committed to regular industry workshops, faster claim disbursals, and robust support to stakeholders paving the road for a self-reliant and globally competitive auto sector," he added. Officials said claims worth ₹322 crore were released under the scheme goals achieved in FY24 to Tata Motors , M&M, Ola Electric, and Toyota Kirloskar Auto Parts (TKAP). This is despite more than 80 companies initially getting approvals under the scheme. The Centre approved the PLI for automobiles in September 2021 with a ₹25,938 crore budgetary outlay. The scheme aims to overcome cost disabilities of the domestic industry for manufacturing Advanced Automotive Technology (AAT) products in India. The industry needs to make fresh investments for indigenous manufacturing of AAT products and create jobs to claim incentives.
NDTV
08-06-2025
- General
- NDTV
JEE Advanced AAT Result 2025 Declared, Check Direct Link To Download
JEE Advanced AAT Result 2025: The Indian Institute of Technology (IIT) Kanpur has declared the results for the JEE Advanced Architecture Aptitude Test (AAT) 2025. Candidates who appeared for the AAT exam can now check and download their scorecards by visiting the official JEE Advanced website at To access their results, candidates will need to log in using their JEE Advanced 2025 registration number, date of birth, and registered mobile number. Direct Link to Check JEE Advanced AAT Result 2025: JEE Advanced AAT Result 2025: Admission Eligibility for Programme Candidates who qualify in the JEE Advanced AAT 2025 will be eligible for admission to the Bachelor of Architecture ( programmes offered at the following Indian Institutes of Technology: IIT BHU, Varanasi IIT Kharagpur IIT Roorkee In addition to passing the AAT, candidates must also meet the minimum marks criteria in their Class 12 board examination. General and OBC category candidates must have secured at least 75 percent marks, while candidates from SC, ST, and PwD categories must have obtained a minimum of 65 percent. JEE Advanced AAT Result 2025: Seat Allocation Process Seats in the programme will be allotted based on the candidate's category-wise All India Rank (AIR) in JEE Advanced 2025. Only those candidates who have qualified the AAT will be considered for admission through this process. Steps To Check JEE Advanced AAT Result 2025 Step 1. Visit the official JEE Advanced website at Step 2. Click on the "JEE Advanced AAT Result 2025" link on the homepage. Step 3. You will be redirected to a new login page. Step 4. Enter your registration number, date of birth, and password. Step 5. Your result will appear on the screen. Step 6. Download and save the scorecard for future reference. Candidates are advised to regularly check the official website for any updates related to the admission process, counselling schedule, and further instructions issued by the authorities.
